跳至主要内容
临床试验/CTRI/2020/06/025768
CTRI/2020/06/025768已完成2 期

An open label Randomized Controlled Clinical trial to Evaluate the Safety and Efficacy of selected Siddha formulations in patients diagnosed with COVID-19

ational Institute of Siddha0 个研究点目标入组 215 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
入组人数
215

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Male, Female and Transgenders.
  • ï?· Age between 18 to 85 years
  • ï?· COVID 19 positive asymptomatic / pre symptomatic, mild, moderate and severe COVID patients.
  • ï?· Willing to consent to the study.

排除标准

  • Patients who cannot take food or drugs orally. High risk groups (Patients with Complications of Diabetes â?? DKA, DN, Severe Heart diseases and Pregnancy)
  • Patients with other severe medical conditions requiring intensive management.
  • Other viral pneumonia
  • Patients who have received organ transplantation in the past 6 months or planning surgery
  • Patients with severe or critical covid-19 infections.
  • Patients with any active malignancy
  • Patients who have severe underlying diseases that affects survival, including blood diseases,
  • dyscrasia, active bleeding, severe malnutrition, etc.
  • Patients with allergic constitution, or patients allergic to investigational products
  • Patients with a history of positivity for HIV, Hepatitis B and Hepatitis C at screening.
  • Critical patients with life expectancy <48 hours
  • Septicemia / Multi-organ failure Syndrome (MODS).
  • Patients whose ALT/AST levels are 5 times higher than the normal upper limit and total bilirubin is 3 times higher than the upper limit of normal.
  • Patients participating in other COVID 19 trials.

研究者

相似试验

An open label Randomized Controlled Clinical trial... | 临床试验